Enalaprilat-mediated activation of kinin B1 receptors and vasodilation in the rat isolated perfused kidney

Pharmacology

Volumn 87, Issue 3-4, 2011, Pages 195-203

  Bautista Pérez, Rocio ^a   Arellano, Abraham ^a   Franco, Martha ^a   Osorio, Horacio ^a   Coronel, Israel ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Angiotensin converting enzyme inhibitors; Bradykinin; des Arg9 BK; Diabetes; Kidney; Nitric oxide

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; ENALAPRILAT; ICATIBANT; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; GENE EXPRESSION; KIDNEY; KIDNEY PERFUSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; STREPTOZOCIN DIABETES; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOTTING, WESTERN; BRADYKININ; DIABETES MELLITUS, EXPERIMENTAL; ENALAPRILAT; KIDNEY; MALE; NITRIC OXIDE; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION; VASODILATION;

EID: 79952857425     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324513     Document Type: Article

References (47)

1. Vora JP, Oyama TT, Thompson MM, Anderson S: Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Diabetes1997; 46: 107-112. (Pubitemid 27009957)
2. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME: Role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes 1997; 46: 1612-1618.
3. Tschöpe C, Reinecke A, Seidl U, Yu M, Gavriluk V, Riester U, Gohlke P, Graf K, Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, Unger T: Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats. Am J Physiol 1999; 277: H2333-H2340. (Pubitemid 30048154)
4. Wiecek A, Chudek J, Kokot F: Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications. Nephrol Dial Transplant 2003; 18:v16-v20. (Pubitemid 36896442)
5. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw B: International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77. (Pubitemid 40283969)
6. Kakoki M, Takahashi N, Jennette JC, Smithies O: Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B 2 receptor. Proc Natl Acad Sci USA 2004; 101: 13302-13305. (Pubitemid 39209660)
7. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, Hua K, Gasim AM, Tomita H,Grant R, Nossov SB, Kim HS, Jennette JC, Feldman EL, Smithies O: Lack of both bradykinin B 1 and B 2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci USA 2010; 107: 10190-10195.
8. Tan Y, Wang B, Keum JS, Jaffa AA: Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 2005; 288:F483-F492. (Pubitemid 40279454)
9. Tang SC, Chan LY, Leung JC, Cheng AS, Chan KW, Lan HY, Lai KN: Bradykinin and high glucose promote renal tubular inflammation. Nephrol Dial Transplant 2010; 25: 698-710.
10. Tan Y, Keum JS, Wang B, McHenry MB, Lipsitz SR, Jaffa AA: Targeted deletion of B 2 -kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 2007; 293:F1026-F1035. (Pubitemid 47583934)
11. Briner VA, Tsai P, Schrier RW: Bradykinin: potential for vascular constriction in the presence of endothelial injury. Am J Physiol 1993; 264:F322-F327. (Pubitemid 23068492)
12. Rodríguez AI, Pereira-Flores K, Hernández- Salinas R, Boric MP, Velarde V: High glucose increases B 1 -kinin receptor expression and signaling in endothelial cells. Biochem Biophys Res Commun 2006; 345: 652-659. (Pubitemid 43776984)
13. Fernandes L, Ceravolo GS, Fortes ZB, Tostes R, Santos RA, Santos JA, Mori MA,Pesquero JB, de Carvalho MH: Modulation of kinin B 1 receptor expression by endogenous angiotensin II in hypertensive rats. Regul Pept 2006; 136: 92-97.
14. Ceravolo GS, Fernandes L, Munhoz CD, Fernandes DC, Tostes RC, Laurindo FR,Scavone C, Fortes ZB, Carvalho MH: Angiotensin II chronic infusion induces B 1 receptor expression in aorta of rats. Hypertension 2007; 50: 756-761. (Pubitemid 47442742)
15. Christopher J, Velarde V, Zhang D, Mayfield D, Mayfield RK, Jaffa AA: Regulation of B(2)-kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2001; 280:H1537-H1546.
16. Tan Y, Hutchison FN, Jaffa AA: Mechanisms of angiotensin II-induced expression of B2 kinin receptors. Am J Physiol Heart Circ Physiol 2004; 286:H926-H932. (Pubitemid 38248605)
17. Mage M, Pécher C, Neau E, Cellier E, Dos Reiss ML, Schanstra JP, Couture R, Bascands JL, Girolami JP: Induction of B 1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemiainduced glomerular Erk 1 and 2 phosphorylation. Can J Physiol Pharmacol 2002; 80: 328-333. (Pubitemid 34451249)
18. Cellier E, Mage M, Duchêne J, Pécher C, Couture R, Bascands JL, Girolami JP: Bradykinin reduces growth factor-induced glomerular ERK1/2 phosphorylation. Am J Physiol Renal Physiol 2003; 284:F282-F292. (Pubitemid 36114691)
19. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Ervin G, Erdös EG: novel mode of action of angiotensin I converting enzyme inhibitors. J Biol Chem 2002; 277: 16847-16852.
20. Hoffmann G, Pietsch R, Göbel BO, Weisser B, Bönner G, Vetter H, Diising R: Converting enzyme inhibition and vascular prostacyclin synthesis: effect of kinin receptor antagonism. Eur J Pharmacol 1990; 178: 79-83. (Pubitemid 20095714)
21. Osorio H, Bautista R, Rios A, Franco M, Santamaría J, Escalante B: Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 2009; 86:e46-e49.
22. Bautista R, Sánchez A, Hernández J, et al: Angiotensin II type AT2 receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension 2001; 38: 669-673.
23. Drummond GR, Cocks TM: Endotheliumdependent relaxations mediated by inducible B 1 and constitutive B 2 kinin receptors in the bovine isolated coronary artery. Br J Pharmacol 1995; 116: 2473-2481.
24. Fortes ZB, Garcia Leme J, Scivoletto R: Influence of diabetes on the reactivity of mesenteric microvessels to histamine, bradykinin and acetylcholine. Br J Pharmacol 1983; 78: 39-48. (Pubitemid 13167575)
25. Fortes ZB, Garcia Leme J, Scivoletto R: Vascular reactivity in diabetes mellitus: role of the endothelial cell. Br J Pharmacol 1983; 79: 771-781.
26. Fortes ZB, Scivoletto R, Garcia-Leme J: Functional changes in the microcirculation of alloxan-induced diabetic rats. Gen Pharmacol 1989; 20: 615-620. (Pubitemid 19232598)
27. Heygate KM, Lawrence IG, Bennett MA, Thurston H: Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats. Br J Pharmacol 1995; 116: 3251-3259. (Pubitemid 26007770)
28. Toledo DP, Akamine E, Nigro D, Passaglia RC, Carvalho MH, Fortes ZB: Microvascular reactivity in experimental diabetes: responses of male and female rats. Inflamm Res 2003; 52: 191-198. (Pubitemid 36712963)
29. Abdouh M, Khanjari A, Abdelazziz N, Ongali B, Couture R, Hasséssian HM: Early upregulation of kinin B 1 receptors in retinal microvessels of the streptozotocin-diabetic rat. Br J Pharmacol 2003; 140: 33-40. (Pubitemid 37175828)
30. Lamontagne D, Nakhostine N, Couture R, Nadeau R: Mechanisms of kinin B 1 -receptorinduced hypotension in the anesthetized dog. J Cardiovasc Pharmacol 1996; 28: 645-650. (Pubitemid 26397022)
31. Oh-ishi S, Tokumasu T, Ueno A: Induction of a B1-receptor mediating hypotensive response in young brown Norway rats. Immunopharmacology 1996; 33: 101-103. (Pubitemid 26247907)
32. Su JB, Hoüel R, Héloire F, Barbe F, Beverelli F, Sambin L, Castaigne A, Berdeaux A, Crozatier B, Hittinger L: Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation. Circulation 2000; 101: 1848-1853. (Pubitemid 30213108)
33. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H: Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res 2001; 88: 275-281. (Pubitemid 32173750)
34. Duka I, Duka A, Kintsurashvili E, Johns C, Gavras I, Gavras H: Mechanisms mediating the vasoactive effects of the B1 receptors of bradykinin. Hypertension 2003; 42: 1021-1025. (Pubitemid 37413747)
35. Christopher J, Jaffa AA: Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol 2002; 2: 1771-1779. (Pubitemid 35373920)
36. Allard J, Buléon M, Cellier E, Renaud I, Pecher C, Praddaude F, Conti M, Tack I, Girolami JP: ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B 2 -kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007; 293:F1083-F1092. (Pubitemid 47583940)
37. Buléon M, Allard J, Jaafar A, Praddaude F, Dickson Z, Ranera MT, Pecher C, Girolami JP, Tack I: Pharmacological blockade of B 2 - kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 2008; 294:F1249-F1256.
38. Ura N, Carretero OA, Erdös EG: Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987; 32: 507-513. (Pubitemid 17154740)
39. Fortin JP, Gobeil F Jr, Adam A, Regoli D, Marceau F: Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B 1 receptor? Am J Physiol Heart Circ Physiol 2003; 285:H277-H282. (Pubitemid 36736439)
40. Morissette G, Couture J, Désormeaux A, Adam A, Marceau F: Lack of direct interaction between enalaprilat and the kinin B 1 receptors. Peptides 2008; 29: 606-612.
41. Ignjatovic T, Stanisavljevic S, Brovkovych V, Skidgel RA, Erdös EG: Kinin B 1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol 2004; 66: 1310-1316. (Pubitemid 39411071)
42. Magen E, Viskoper RJ: Interactions of angiotensin- converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases. Isr Med Assoc J 2000; 2: 929-934. (Pubitemid 34182785)
43. Yoshikawa H: Renal angiotensin converting enzyme (ACE) expression in diabetic rats: the effect of ACE inhibitors. Nippon Jinzo Gakkai Shi 1999; 41: 486-492. (Pubitemid 29459362)
44. Maeda S, Kikkawa R, Haneda M, Togawa M, Koya D, Horide N, Kajiwara N, Uzu T, Shigeta Y: Reduced activity of renal angiotensinconverting enzyme in streptozotocin-induced diabetic rats. J Diabet Complications 1991; 5: 225-229.
45. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D: Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004; 43: 1120-1125. (Pubitemid 38579924)
46. Huang XR, Chen WY, Truong LD, Lan HY: Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14: 1738-1747. (Pubitemid 36750469)
47. Schäfer S, Schmidts HL, Bleich M, Busch AE, Linz W: Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B 2 receptor dependent. Br J Pharmacol 2004; 143: 27-32. (Pubitemid 39280021)